Dissociated incretin hormone response to protein versus fat ingestion in obese subjects

Diabetes, Obesity and Metabolism

Volumn 13, Issue 9, 2011, Pages 863-865

  Lindgren, O ^a   Carr, R D ^b   Holst, J J ^c   Deacon, C F ^c   Ahren B ^a  

^a LUND UNIVERSITY   (Sweden)

^b MSD A/S   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Glucagon like peptide 1; Glucose dependent insulinotropic polypeptide; Incretins; Insulin; Lipid; Man; Obesity; Protein

Indexed keywords

GLUCAGON LIKE PEPTIDE; INCRETIN; OLIVE OIL; PROTEIN DERIVATIVE; UNCLASSIFIED DRUG; WHEY PROTEIN;

ARTICLE; BODY MASS; CLINICAL ARTICLE; FAT INTAKE; HORMONE RESPONSE; HUMAN; MALE; OBESITY; PROTEIN INTAKE; PROTEIN SECRETION; WHEY;

EID: 79960823117     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2011.01420.x     Document Type: Article

References (11)

1. Drucker DJ. The biology of incretin hormones. Cell Metab 2006; 3: 153-165.
2. Deacon CF. What do we know about the secretion and degradation of incretin hormones? Regul Pept 2005; 128: 117-125.
3. Carr RD, Larsen MO, Jelic K et al. Secretion and dipeptidyl peptidase-4-mediated metabolism of incretin hormones after a mixed meal or glucose ingestion in obese compared to lean, nondiabetic men. J Clin Endocrinol Metab 2010; 95: 872-878.
4. Carr RD, Larsen MO, Winzell MS et al. Incretin and islet hormonal responses to fat and protein ingestion in healthy men. Am J Physiol Endocrinol Metab 2008; 295: E779-E784.
5. Vilsbøll T, Krarup T, Sonne J et al. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab 2003; 88: 2706-2713.
6. Ranganath LR, Beety JM, Morgan LM, Wright JW, Howland R, Marks V. Attenuated GLP-1 secretion in obesity: cause or consequence? Gut 1996; 38: 916-919.
7. 2-terminus in type II diabetic patients and in healthy subjects. Diabetes 1995; 44: 1126-1131.
8. Deacon CF, Nauck MA, Meier J, Hucking K, Holst JJ. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab 2000; 85: 3575-3581.
9. Tolhurst G, Reimann F, Gribble FM. Nutritional regulation of glucagon-like peptide-1 secretion. J Physiol 2009; 587: 27-32.
10. Irwin N, Flatt PR. Evidence for beneficial effects of compromised gastric inhibitory polypeptide action in obesity-related diabetes and possible therapeutic implications. Diabetologia 2009; 52: 1724-1731.
11. Creutzfeldt W, Ebert R. New developments in the incretin concept. Diabetologia 1985; 28: 565-573.